The main drivers for the improvement were reduction in the costs of goods sold and better inventory management
Financial Highlights
| Q1FY19 | Q1FY18 | Growth | FY18 | |
| Net Sales (INR Crore) | 38.26 | 29.04 | 32% | 135.25 |
| Net Profit (INR Crore) | 9.68 | 6.15 | 57% | 30.56 |
| EPS (INR) | 11.38 | 7.23 | 57% | 35.92 |
Q1 Highlights
· Hester has reported a Net Sales of INR 38.26 crore in Q1FY19 as compared to INR 29.04 crore for the previous corresponding period, thereby registering a growth of 32 per cent.
· Net Profit for Q1FY19 is recorded at INR 9.68 crore as against INR 6.15 crore for the previous corresponding period, thereby registering a growth of 57 per cent.
· Earnings per Share for the Q1FY19 are at INR 11.38 as against INR 7.23 for Q1FY18.
· Net Profit margin for Q1FY19 is at 25.31 per cent of sales as against 21.18 per cent in Q1FY18.
Business Overview
Hester India operations
· The top-line growth can be attributed to the commissioning of the expanded capacity and shifting the focus on high value products.
· The company improved its EBIDTA and the Net Profit in Q1FY19. The main drivers for the improvement were reduction in the costs of goods sold, better inventory management, rationalising the product mix and better credit control.
· Considering the high profitability in Q1 and being reasonably confident of maintaining this level, the board declared an interim dividend of 20 percent (INR 2 per share) for the current financial year.
· Various inorganic growth opportunities in the sphere of animal health manufacturing and distribution are currently being explored. The company hopes to grow its business either towards increasing its market penetration with additional products or towards increasing the geographical market reach.
Hester Nepal operations
· Nepal plant has started generating revenues leading to a positive EBIDTA level.
· Hester Nepal received manufacturing and marketing authorisations for four additional animal vaccines
Hester Africa operations
The animal vaccine manufacturing project in Tanzania has been finalised. The first commercial batch is slated to be released in 2020 end. This plant would be the first of its kind in Africa to address many prevailing diseases in the continent. The plant is designed to generate a top-line of USD 30 million at full capacity.